Topiramate monotherapy in infantile spasms

초록

We administered Topiramate (TPM) as monotherapy to twenty patients with newly diagnosed infantile spasms. This study included 17 boys amd 3 girls, ranging in age from 3 to 24 months (mean age, 11 months). Regarding the etiology, cryptogenic group was 40%, and symptomatic 60%. Six (30%) patients became seizure free, eight (40%) patients achieved a seizure reduction of >50%, spasm frequency decreased from 10.6 +/- 8.5 to 3.5 +/- 1.4 spasms/day. Adverse effects during titration and stabilization included sleep disturbance, lethargy, irritability, rash, and oligohidrosis. TPM is effective and tolerated in patients with infantile spasm. Our results suggest that TPM may be considered a new first-line drug in infantile spasm.